<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624569</url>
  </required_header>
  <id_info>
    <org_study_id>2018H0265</org_study_id>
    <nct_id>NCT03624569</nct_id>
  </id_info>
  <brief_title>Cardiometabolic Benefits of Potatoes Mediated Along the Gut-Vessel Axis in Adults With Metabolic Syndrome</brief_title>
  <official_title>Cardiometabolic Benefits of Potatoes Mediated Along the Gut-Vessel Axis in Adults With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alliance for Potato Research and Education</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is focused on assessing potential health benefits of daily consumption of
      potatoes, specifically its resistant starch content (i.e. nondigestible carbohydrate), on
      blood vessel and gut health function in adults with metabolic syndrome. It is expected that
      the daily consumption of potatoes for two weeks, within a diet that follows the Dietary
      Guidelines for Americans, will improve blood vessel function in association with decreasing
      gut permeability (&quot;leaky gut&quot;) that results in the absorption of bacterial toxins that reside
      in the intestine. Outcomes will therefore support dietary recommendations for potatoes to
      support vascular and gastrointestinal health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease is a major public health concern in the United States, where it
      accounts for 1 in 4 deaths every year. Vascular endothelial dysfunction is an early event
      leading to cardiovascular disease and can be caused by postprandial hyperglycemia.
      Cardiovascular disease is also characterized by metabolic endotoxemia. Metabolic endotoxemia
      describes increased circulating levels of gut-derived endotoxin (lipopolysaccharide; a
      bacterial product derived from Gram-negative bacteria in the intestines) that results from
      gut barrier dysfunction, a phenomenon that is common in metabolic syndrome. Studies in
      animals and humans have shown that consumption of resistant starch (a type of carbohydrate
      found in potatoes among other foods) can help to improve vascular and gut health. This
      clinical trial will therefore investigate the extent to which potatoes can improve microbiota
      composition, alleviate metabolic endotoxemia, and improve vascular function. It is
      hypothesized that 2-week daily ingestion of potatoes within a diet that meets the Dietary
      Guidelines for Americans will limit metabolic endotoxemia by decreasing gut barrier
      permeability and alleviating gut dysbiosis while separately improving vascular function by
      limiting postprandial hyperglycemia. This study will address the following objectives: 1)
      define changes in gut barrier function in association with improved gut microbiota
      composition, increased fecal short chain fatty acid (SCFA) production, and decreased serum
      endotoxin, 2) define changes in postprandial glycemic responses and endotoxemia, and 3)
      define changes in gut hormones that promote glycemic control and changes in markers of
      oxidative stress in relation to improvements in endothelial vascular function, all following
      2-week potato consumption. To test the hypothesis, all participants will complete a
      randomized cross-over trial where they will receive a potato or bagel along with a diet that
      meets the Dietary Guidelines for Americans for 2 weeks. They will then undergo a 2-h
      postprandial study to define the influence of potato consumption on vascular function,
      glycemic control, and endotoxin translocation. Upon completing the intervention, participants
      will undergo a gut permeability test, fecal samples will be collected for microbiota
      composition analysis, and blood samples will be collected to assess endotoxin and
      inflammatory markers. Upon successfully completing this study, it is anticipated that chronic
      consumption of potatoes will be demonstrated to be an effective dietary strategy to reduce
      metabolic endotoxemia, improve gut health, and improve vascular function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endotoxin</measure>
    <time_frame>Day 14</time_frame>
    <description>Fasting serum endotoxin concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular endothelial function</measure>
    <time_frame>Day 14 Postprandial (0, 30, 60, 90, 120 minutes)</time_frame>
    <description>Area under curve (change from baseline) for flow-mediated dilation of brachial artery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose Day 0</measure>
    <time_frame>Fasting glucose on Day 0</time_frame>
    <description>Fasting plasma glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose Day 14</measure>
    <time_frame>Fasting glucose on Day 14</time_frame>
    <description>Fasting plasma glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin Day 0</measure>
    <time_frame>Fasting insulin on Day 0</time_frame>
    <description>Fasting plasma insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin Day 14</measure>
    <time_frame>Fasting insulin on Day 14</time_frame>
    <description>Fasting plasma insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Insulin</measure>
    <time_frame>Day 14 postprandial (0, 30, 60, 90, 120 minutes)</time_frame>
    <description>Plasma insulin concentration area under curve change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Glucose</measure>
    <time_frame>Day 14 postprandial (0, 30, 60, 90, 120 minutes)</time_frame>
    <description>Postprandial plasma glucose concentration area under curve change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Endotoxin</measure>
    <time_frame>Day 0</time_frame>
    <description>Fasting serum endotoxin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Endotoxin</measure>
    <time_frame>Day 14 postprandial (0, 30, 60, 90, 120 minutes)</time_frame>
    <description>Postprandial serum endotoxin concentration area under curve change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactulose/mannitol ratio</measure>
    <time_frame>Day 14, 0-5 hours post-consumption of sugar probes</time_frame>
    <description>Urinary concentration of the non-digestible sugars lactulose/mannitol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sucralose/erythritol ratio</measure>
    <time_frame>Day 14, 6-24 hours post-consumption of sugar probes</time_frame>
    <description>Urinary concentration of the non-digestible sugars sucralose/erythritol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal butyrate</measure>
    <time_frame>Day 14</time_frame>
    <description>Fecal concentration of butyrate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal acetate</measure>
    <time_frame>Day 14</time_frame>
    <description>Fecal concentration of acetate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal propionate</measure>
    <time_frame>Day 14</time_frame>
    <description>Fecal concentration of propionate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Cholecystokinin</measure>
    <time_frame>Day 14 postprandial (0, 30, 60, 90, 120 minutes)</time_frame>
    <description>Plasma CCK area under curve change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial glucagon-like peptide-1</measure>
    <time_frame>Day 14 postprandial (0, 30, 60, 90, 120 minutes)</time_frame>
    <description>Plasma GLP-1 area under curve change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Gastric inhibitory peptide</measure>
    <time_frame>Day 14 postprandial (0, 30, 60, 90, 120 minutes)</time_frame>
    <description>Plasma GIP area under curve change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting cholecystokinin</measure>
    <time_frame>Day 14</time_frame>
    <description>Fasting plasma concentration of CCK</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting GLP-1</measure>
    <time_frame>Day 14</time_frame>
    <description>Fasting plasma concentration of GLP-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Gastric inhibitory peptide</measure>
    <time_frame>Day 14</time_frame>
    <description>Fasting plasma concentration of GIP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial NOx</measure>
    <time_frame>Day 14 postprandial (0, 30, 60, 90, 120 minutes)</time_frame>
    <description>Plasma total nitrite/nitrate area under curve change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting NOx</measure>
    <time_frame>Day 14</time_frame>
    <description>Fasting plasma concentration of nitrite/nitrate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Malondialdehyde (MDA)</measure>
    <time_frame>Day 14 postprandial (0, 30, 60, 90, 120 minutes)</time_frame>
    <description>Plasma MDA concentration, biomarker of oxidative stress area under curve change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Malondialdehyde (MDA)</measure>
    <time_frame>Day 14</time_frame>
    <description>Fasting plasma MDA concentration, biomarker of oxidative stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Vascular Endothelial Function</measure>
    <time_frame>Day 14</time_frame>
    <description>Fasting flow-mediated dilation of the brachial artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin C</measure>
    <time_frame>Day 14</time_frame>
    <description>Fasting vitamin C concentration, biomarker of oxidative stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cIMT</measure>
    <time_frame>Day 14</time_frame>
    <description>Carotid intima-media thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 0 weight</measure>
    <time_frame>Day 0</time_frame>
    <description>Weight in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 7 weight</measure>
    <time_frame>Day 7</time_frame>
    <description>Weight in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 14 weight</measure>
    <time_frame>Day 14</time_frame>
    <description>Weight in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 0 height</measure>
    <time_frame>Day 0</time_frame>
    <description>Height in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 7 height</measure>
    <time_frame>Day 7</time_frame>
    <description>Height in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 14 height</measure>
    <time_frame>Day 14</time_frame>
    <description>Height in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 0 waist circumference</measure>
    <time_frame>Day 0</time_frame>
    <description>Waist circumference in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 7 waist circumference</measure>
    <time_frame>Day 7</time_frame>
    <description>Waist circumference in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 14 waist circumference</measure>
    <time_frame>Day 14</time_frame>
    <description>Waist circumference in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 0 diastolic blood pressure</measure>
    <time_frame>Day 0</time_frame>
    <description>Diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 7 diastolic blood pressure</measure>
    <time_frame>Day 7</time_frame>
    <description>Diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 14 diastolic blood pressure</measure>
    <time_frame>Day 14</time_frame>
    <description>Diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 0 systolic blood pressure</measure>
    <time_frame>Day 0</time_frame>
    <description>Systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 7 systolic blood pressure</measure>
    <time_frame>Day 7</time_frame>
    <description>Systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 14 systolic blood pressure</measure>
    <time_frame>Day 14</time_frame>
    <description>Systolic blood pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Endotoxemia</condition>
  <condition>Endothelial Dysfunction</condition>
  <condition>Postprandial Hyperglycemia</condition>
  <condition>Gut Health</condition>
  <arm_group>
    <arm_group_label>Bagel diet</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Bagel consumed daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Potato diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Potato consumed daily for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bagel</intervention_name>
    <description>A bagel will be consumed daily for 2 weeks.</description>
    <arm_group_label>Bagel diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Potato</intervention_name>
    <description>A potato will be consumed daily for 2 weeks.</description>
    <arm_group_label>Potato diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fasting glucose 100-125 mg/dL

          -  Waist circumference &gt;102 cm (men), &gt;88 cm (women)

          -  Fasting triglyceride &gt;150 mg/dL

          -  Fasting HDL cholesterol &lt;40 mg/dL (men), &lt;50 mg/dL (women)

          -  Non-smoker

          -  Non-dietary supplement user (&gt;1-mo)

          -  Free of gastrointestinal disorders, cardiovascular disease, cancer

          -  No recent use of antibiotics or any medications affecting glycemia, lipidemia, or
             blood pressure

        Exclusion Criteria:

          -  Use of anti-inflammatory agents or probiotics

          -  Vegetarian, gluten-intolerant, carbohydrate-restricted diet

          -  Alcohol intake &gt;2 drinks/d

          -  &gt;7 hours/week of aerobic activity

          -  Women who are pregnant or lactating or have initiated or changed birth control in the
             past 3-months

          -  Taking medications that affect blood sugar, blood pressure, blood vessel health, or
             inflammation

          -  High blood pressure or any vascular diseases

          -  HIV, hepatitis, or blood disorders such as hemophilia

          -  Gastrointestinal disorders

          -  Cancer (current or past history)

          -  Anemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Bruno, PhD, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Bruno, PhD, RD</last_name>
    <phone>6142921698</phone>
    <email>bruno.27@osu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emily Shaw, BS</last_name>
    <phone>5736737269</phone>
    <email>shaw.876@buckeyemail.osu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Bruno, PhD, RD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001 Feb 12;161(3):397-405.</citation>
    <PMID>11176766</PMID>
  </reference>
  <reference>
    <citation>Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despr√©s JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015 Jan 27;131(4):e29-322. doi: 10.1161/CIR.0000000000000152. Epub 2014 Dec 17. Erratum in: Circulation. 2015 Jun 16;131(24):e535. Circulation. 2016 Feb 23;133(8):e417.</citation>
    <PMID>25520374</PMID>
  </reference>
  <reference>
    <citation>Camire ME, Kubow S, Donnelly DJ. Potatoes and human health. Crit Rev Food Sci Nutr. 2009 Nov;49(10):823-40. doi: 10.1080/10408390903041996. Review.</citation>
    <PMID>19960391</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 2, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Richard Bruno</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endotoxemia</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will be published as aggregate only. Data sharing may be possible pending institutional agreements.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

